Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cohort 3A

Phase 1

UUniversity of Pennsylvania

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell LeukemiaActive, not recruiting

B-Cell LeukemiaPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2037

Phase 1Active, not recruiting

B-Cell Leukemia

NCT02650414

Clinical

Trials by Indication[1]

B-Cell Leukemia1 trial

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT02650414·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cohort 3A. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cohort 3A. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

Related News